Details

<p>Foreword to the Second Edition xi<br /><i>by Michael J. Borowitz</i></p> <p>Foreword to the First Edition xii<br /><i>by Maryalice Stetler-Stevenson</i></p> <p>Foreword to the First Edition xiii<br /><i>by Bruno Brando</i></p> <p>Preface to the Second Edition xv</p> <p>Preface to the First Edition xvi</p> <p>Abbreviations xvii</p> <p><b>1 Antigens 1</b></p> <p>Clustered (CD) Antigens</p> <p>CD1 3</p> <p>CD2 5</p> <p>CD3 8</p> <p>CD4 17</p> <p>CD5 21</p> <p>CD7 24</p> <p>CD8 26</p> <p>CD10 30</p> <p>CD11b 35</p> <p>CD11c 38</p> <p>CD13 40</p> <p>CD14 44</p> <p>CD15 46</p> <p>CD16 49</p> <p>CD19 52</p> <p>CD20 55</p> <p>CD22 59</p> <p>CD23 61</p> <p>CD24 64</p> <p>CD25 66</p> <p>CD26 67</p> <p>CD27 69</p> <p>CD28 70</p> <p>CD30 71</p> <p>CD33 73</p> <p>CD34 77</p> <p>CD38 79</p> <p>CD43 81</p> <p>CD45 82</p> <p>CD45 Isoforms 87</p> <p>CD49 90</p> <p>CD56 93</p> <p>CD57 96</p> <p>CD61 97</p> <p>CD62L 98</p> <p>CD64 99</p> <p>CD65 101</p> <p>CD66c 102</p> <p>CD71 103</p> <p>CD79 104</p> <p>CD81 107</p> <p>CD103 108</p> <p>CD117 110</p> <p>CD123 112</p> <p>CD138 113</p> <p>CD200 114</p> <p>CD305 116</p> <p>CD307 (IRTA) Antigen Family 117</p> <p>CD371 118</p> <p>Non clustered (or primarily known with other names) antigens Bcl‐2 Protein 119</p> <p>Chemokines and Chemokine Receptors 121</p> <p>CRLF2 128</p> <p>Cytotoxic Proteins 129</p> <p>HLA‐DR 130</p> <p>Immunoglobulins 132</p> <p>KIR, CD158 isoforms 136</p> <p>Myeloperoxidase (MPO) 139</p> <p>NG2 140</p> <p>PCA‐1 141</p> <p>ROR1 141</p> <p>SLAM Molecules and SLAM‐associated Protein (SAP) 142</p> <p>SOX11 144</p> <p>T‐cell Receptor (TCR) 145</p> <p>Terminal Deoxy‐nucleotidyl‐transferase (TdT) 148</p> <p>Toll‐like Receptors (TLR) 150</p> <p>VS38 151</p> <p>ZAP‐70 152</p> <p><b>2 Diseases 155</b></p> <p>Myeloproliferative neoplasms 157</p> <p>Chronic myeloid leukemia (CML) 157</p> <p>Myeloproliferative neoplasms other than CML 160</p> <p>Chronic neutrophilic leukemia (CNL) 160</p> <p>Polycythemia vera (PV) 160</p> <p>Primary myelofibrosis (PMF) 160</p> <p>Essential thrombocythemia (ET) 160</p> <p>Chronic eosinophilic leukemia (CEL) 161</p> <p>Mastocytosis 162</p> <p>Acute mast‐cell leukemia (AMCL) 162</p> <p>Chronic mast‐cell leukemia (CMCL) 163</p> <p>Myelomastocytic leukemia (MML) 163</p> <p>Myelodysplastic/myeloproliferative neoplasms 164</p> <p>Chronic myelomonocytic leukemia (CMML) 164</p> <p>Other myelodysplastic/myeloproliferative neoplasms and related conditions 167</p> <p>Juvenile myelomonocytic leukemia (JMML) 167</p> <p>Atypical CML bcr/abl negative (ACML) 167</p> <p>RAS‐associated autoimmune leukoproliferative disorder (RALD) 167</p> <p>Myelodysplastic syndromes 168</p> <p>Myeloid neoplasms with germline predisposition 171</p> <p>Acute myeloid leukemias 172</p> <p>AMLs with recurrent genetic anomalies 173</p> <p>AMLs with chromosomal anomalies 173</p> <p>AMLs with gene mutations 180</p> <p>Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 181</p> <p>AMLs with myelodysplasia‐related changes (AML‐MRC) 182</p> <p>AMLs not otherwise specified 182</p> <p>AML with minimal differentiation 182</p> <p>AML without maturation 183</p> <p>AML with maturation 183</p> <p>Acute myelomonocytic leukemia (AMMoL) 183</p> <p>Acute monoblastic and monocytic leukemia (AMoL) 184</p> <p>Pure erythroid leukemia (PEL) 185</p> <p>Acute megakaryoblastic leukemia (AMKL) 186</p> <p>Acute basophilic leukemia (ABL) 188</p> <p>Myeloid proliferations associated with Down syndrome 188</p> <p>Transient abnormal myelopoiesis (TAM) 189</p> <p>AMLs in patients with Down syndrome 189</p> <p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) 189</p> <p>Acute leukemias with ambiguous lineage attribution (ALAL) 192</p> <p>Acute undifferentiated leukemias (AUL) 192</p> <p>Mixed phenotype acute leukemias (MPAL) 192</p> <p>Neoplastic diseases of B and T lymphatic precursors 194</p> <p>B lymphoblastic leukemia/lymphoma, not otherwise specified (B‐ALL/LBLnos) 195</p> <p>B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies 197</p> <p>Relationships between genotype and phenotype in cases of B‐ALL not recognized as separate entities in WHO 2017 201</p> <p>T lymphoblastic leukemia/lymphoma (T‐ALL/LBL) 202</p> <p>Early T‐cell precursor lymphoblastic leukemia (ETP‐ALL) 205</p> <p>NK lymphoblastic leukemia/lymphoma (NK‐ALL/LBL) 205</p> <p>Neoplastic diseases of mature B cells 206</p> <p>Chronic lymphocytic leukemia/small</p> <p>lymphocytic lymphoma (B‐CLL/SLL) 206</p> <p>Familial B‐CLL 215</p> <p>Richter syndrome 215</p> <p>Monoclonal B‐cell lymphocytosis (MBL) 216</p> <p>CLL‐like monoclonal B lymphocytosis 216</p> <p>Non‐CLL‐like monoclonal B lymphocytosis 216</p> <p>B‐cell prolymphocytic leukemia (B‐PLL) 216</p> <p>Lymphoplasmacytic lymphoma (LPL) 218</p> <p>Heavy chain disease (HCD) 221</p> <p>γ heavy chain disease 222</p> <p>μ heavy chain disease 222</p> <p>α heavy chain disease 222</p> <p>Hairy cell leukemia (HCL) 222</p> <p>Hairy cell leukemia, variant (HCL‐v) 226</p> <p>Hairy cell leukemia, Japanese variant (HCL‐J) 227</p> <p>Splenic diffuse red pulp lymphoma (SDRPL) 227</p> <p>Marginal zone lymphomas (MZL) 228</p> <p>Nodal marginal zone lymphoma (NMZL) 229</p> <p>Splenic marginal zone lymphoma (SMZL) 230</p> <p>Extranodal marginal zone lymphoma (EMZL/MALToma) 232</p> <p>Clonal B‐cell lymphocytosis with MZL‐like phenotype (CBL‐MZ) 233</p> <p>Follicular lymphoma (FCL) 234</p> <p>Testicular follicular lymphoma 237</p> <p>Duodenal type follicular lymphoma 237</p> <p>Pediatric type follicular lymphoma 237</p> <p>Primitive cutaneous follicular lymphoma (PCFL) 237</p> <p>Large B‐cell lymphoma with IRF4 rearrangement 237</p> <p>Mantle‐cell lymphoma (MCL) 237</p> <p>Blastic mantle‐cell lymphoma (BMCL) 240</p> <p>Leukemic non nodal mantle‐cell lymphoma 240</p> <p>DLBCL not otherwise specified (DLBCLnos) 240</p> <p>CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) 243</p> <p>T‐cell/histiocyte‐rich B‐cell lymphoma (THRLBCL) 243</p> <p>Primary DLBCL of the CNS (PCNSL) 244</p> <p>Primary cutaneous DLBCL, “leg type” 244</p> <p>EBV(+) DLBCLnos 244</p> <p>DLBCL associated with chronic inflammation (PAL) 245</p> <p>Fibrin associated DLBCL 245</p> <p>Lymphomatoid granulomatosis (LYG) 245</p> <p>Primary mediastinal B‐cell lymphoma (PMBCL) 245</p> <p>Intravascular large B‐cell lymphoma (IVBCL) 246</p> <p>ALK‐positive large cell lymphoma (ALK(+) LBCL) 246</p> <p>Plasmablastic lymphoma (PBL) 247</p> <p>Primary effusion lymphoma (PEL) 247</p> <p>HHV8‐associated lymphoproliferative disorders 247</p> <p>HHV8‐positive DLBCL 248</p> <p>HHV8‐positive germinotropic lymphoproliferative disorder 248</p> <p>Burkitt lymphoma (BL) 248</p> <p>Burkitt leukemia with immature phenotype 250</p> <p>Burkitt‐like lymphoma with 11q aberrations 251</p> <p>High‐grade B‐cell lymphoma (HGBL) 251</p> <p>Plasma cell neoplasms 251</p> <p>Monoclonal gammopathies of undetermined significance (MGUS) 253</p> <p>Multiple myeloma (MM) 253</p> <p>Plasma cell leukemia (PCL) 257</p> <p>Neoplastic diseases of mature T and NK cells 258</p> <p>T‐cell prolymphocytic leukemia (T‐PLL) 258</p> <p>T‐cell large granular lymphocytic leukemia (T‐LGL) 261</p> <p>Chronic lymphoproliferative disorders of NK cells (CLPD‐NK/CNKL) 263</p> <p>Aggressive NK‐cell leukemia (ANKL) 266</p> <p>Adult T‐cell leukemia/lymphoma (ATLL) 266</p> <p>Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL) 269</p> <p>Intestinal T‐cell lymphomas (ITCL) 270</p> <p>Enteropathy‐associated T‐cell lymphoma (EATCL) 270</p> <p>Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) 272</p> <p>Indolent gastro‐intestinal T lymphoproliferative disorder (indolent GI T‐LPD) 273</p> <p>Hepatosplenic T‐cell lymphoma (HSTCL) 273</p> <p>Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) 275</p> <p>Mycosis fungoides (MF) 275</p> <p>Sezary syndrome (SS) 277</p> <p>Primary cutaneous CD30(+) lymphoproliferative disorders 279</p> <p>Lymphomatoid papulosis (LyP) 279</p> <p>Primary cutaneous anaplastic T‐cell lymphoma (pcALCL) 279</p> <p>Primary cutaneous peripheral T‐cell lymphoma (PTCL) 280</p> <p>Primary cutaneous TCRγδ(+) T‐cell lymphoma (PCGD‐TCL) 280</p> <p>Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T‐cell lymphoma (PCAETL) 280</p> <p>Primary cutaneous acral CD8(+) T‐cell lymphoma (PCATCL) 280</p> <p>Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM‐TCL) 281</p> <p>Peripheral T‐cell lymphoma, not otherwise specified (PTCLnos) 281</p> <p>Nodal lymphomas of follicular T‐helper derivation 283</p> <p>Angioimmunoblastic T‐cell lymphoma (AITL) 283</p> <p>Follicular T‐cell lymphoma (FTCL) 285</p> <p>Nodal PTCL with follicular T‐helper phenotype 285</p> <p>Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)) 285</p> <p>Anaplastic large cell lymphoma ALK(‐) (ALCL ALK(‐)) 288</p> <p>Breast implant–associated anaplastic large cell lymphoma (biaALCL) 288</p> <p>Hodgkin lymphomas 289</p> <p>Classic Hodgkin lymphoma (CHL) 289</p> <p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 290</p> <p>Neoplastic diseases of histiocytic and dendritic cells 291</p> <p>Histiocytic sarcoma (HS) 292</p> <p>Langerhans cell histiocytosis (LCH) 292</p> <p>Indeterminate dendritic cell tumor (IDCT) 292</p> <p>Interdigitating dendritic cell sarcoma (IDCS) 292</p> <p>Follicular dendritic cell sarcoma (FDCS) 292</p> <p>Erdheim–Chester disease (EDC) 292</p> <p><b>3 Appendix 293</b></p> <p>Acute leukemias not recognized by the 2017 WHO classification 294</p> <p>Acute leukemia of myeloid/NK precursors (M/NK‐AL) 294</p> <p>Acute leukemia of myeloid dendritic cells (MDCL) 294</p> <p>Acute leukemia of Langerhans cells 294</p> <p>Composite lymphomas 294</p> <p>Hypereosinophilic syndrome (HES), lymphocyte variant 295</p> <p>Indolent T lymphoblastic proliferations (iT‐LBP) 295</p> <p>Polyclonal lymphocytoses of B lymphocytes 298</p> <p>Persistent polyclonal B‐cell lymphocytosis (PPBL) 298</p> <p>Persistent polyclonal CD5(+) B‐cell lymphocytosis 298</p> <p>Persistent polyclonal B‐cell lymphocytosis, Japanese (hairy) variant 298</p> <p>Polyclonal plasmacytoses 299</p> <p>Small round (blue) cell tumors (SR(B)CT) 300</p> <p>References 301</p> <p>Index 429</p>

<p><b>About the author</b></p><p><b>Claudio Ortolani</b> is an expert in the area of diagnosis of hematological malig­­nancies. Now retired, Dr Ortolani was Consultant in the Department of Clinical Pathology at Venice General Hospital, Venice, Italy. He is one of the founding members of the Italian Society for Cytometric Cell Analysis (ISCCA), of whose board he is currently a member. He has taught and lectured internationally on how to use flow cytometry to aid in diagnosing hematological diseases.</p>

<p>Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. <i>Flow Cytometry of Hematological Malignancies</i> has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:</p><ul><li>Explorations of more than 70 antigens</li><li>Full-color illustrations throughout</li><li>New descriptions of recently discovered markers</li><li>WHO classifications of hematological neoplastic diseases</li><li>Helpful tips for result interpretation and analysis</li></ul><p>Featuring all this and more, <i>Flow Cytometry of Hematological Malignancies, Second Edition,</i> is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.</p>

GB